Retatrutide vs Tirzepatide: What the Data Actually Shows
Retatrutide adds a third receptor to Tirzepatide's dual mechanism. That difference produces more weight loss -- and a distinct side effect profile that matters for anyone tracking their protocol carefully.
The Core Difference
Tirzepatide activates two receptors: GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP, and glucagon. That third receptor -- glucagon -- drives additional fat oxidation and energy expenditure, explaining the superior weight loss. It also drives elevated heart rate, which requires monitoring.
How Do Retatrutide and Tirzepatide Work Differently?
Both drugs are incretin-based therapies that reduce appetite and slow gastric emptying. The difference is the number of receptors targeted.
Tirzepatide (dual agonist) activates GLP-1 receptors -- which suppress appetite and regulate blood sugar -- and GIP receptors, which improve insulin sensitivity and may reduce the GI side effects that come with GLP-1 alone. The combination is why Tirzepatide outperforms older GLP-1 drugs like Semaglutide.
Retatrutide (triple agonist) adds glucagon receptor agonism on top of Tirzepatide's dual mechanism. Glucagon increases hepatic glucose production and, critically, drives additional energy expenditure through direct thermogenic effects. This is the mechanism responsible for both Retatrutide's superior fat loss and its cardiovascular side effect profile.
Why the glucagon receptor matters: Glucagon is traditionally thought of as a counterregulatory hormone that raises blood sugar. At the doses used in Retatrutide, the glucagon component is carefully balanced so that blood sugar effects are offset by the GLP-1 component, while the energy expenditure and fat oxidation benefits are preserved. The resting heart rate increase is a direct glucagon cardiovascular effect that does not appear to be offset.
What Do the Weight Loss Results Show?
The Phase 2 SURMOUNT-J trial of Retatrutide demonstrated approximately 24.2% body weight reduction at 24 weeks in participants receiving the highest dose (12mg weekly). The SURMOUNT-1 trial of Tirzepatide showed approximately 20.9% body weight reduction at 72 weeks.
These numbers require careful interpretation. Retatrutide's 24.2% is from a shorter timeframe (24 weeks) with a smaller Phase 2 population. Tirzepatide's 20.9% comes from the large Phase 3 SURMOUNT-1 trial with over 2,500 participants. Direct comparison of the two is not apples-to-apples without a head-to-head trial, which does not yet exist.
The research community has noted, however, that Retatrutide's trajectory appears steeper -- particularly in the first 12 weeks -- suggesting the glucagon component drives faster initial fat loss. Long-term durability data is pending Phase 3 completion.
Retatrutide peak weight loss
~24.2%
Phase 2, 24 weeks, 12mg dose
Tirzepatide peak weight loss
~20.9%
SURMOUNT-1, 72 weeks, 15mg dose
Estimated difference
~3.3pp
Not from head-to-head trial
How Do the Side Effect Profiles Compare?
For most GI side effects, the two drugs are similar. The meaningful difference is cardiovascular -- specifically heart rate.
Shared Side Effects
- •Nausea (most common, typically dose-dependent)
- •Vomiting (peaks during dose escalation)
- •Diarrhea or constipation
- •Reduced appetite
- •Fatigue at higher doses
- •Injection site reactions
Retatrutide-Specific
- •Elevated resting heart rate (+4-5 bpm average)
- •Palpitations reported in Phase 2 participants
- •Requires cardiac monitoring in patients with existing conditions
- •Glucagon-driven: does not appear dose-titration-dependent
Muscle loss: a shared concern. Both drugs suppress appetite enough to cause significant lean mass loss alongside fat loss. Studies suggest GLP-1 agonists may cause 25-40% of total weight loss to come from lean tissue. This is why many clinicians and self-optimizers are stacking both drugs with compounds like Ipamorelin or CJC-1295 to preserve the GH/IGF-1 axis. See the GLP-1 Defense Stack for the evidence-graded protocol.
Head-to-Head Comparison Table
| Metric | Retatrutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 + GIP + Glucagon (triple) | GLP-1 + GIP (dual) |
| FDA Status | Investigational (Phase 3) | FDA Approved (Zepbound, Mounjaro) |
| Avg. Weight Loss | ~24.2% at 24 weeks (Phase 2) | ~20.9% at 72 weeks (SURMOUNT-1) |
| Dosing Frequency | Once weekly (injectable) | Once weekly (injectable) |
| GI Side Effects | Nausea, vomiting, diarrhea | Nausea, vomiting, diarrhea |
| Heart Rate Effect | +4-5 bpm average increase | Minimal effect |
| Compounding Available | No | Yes (limited, varies by shortage status) |
| Typical Starting Dose | 1mg/week (titrating to 12mg) | 2.5mg/week (titrating to 15mg) |
| Muscle Preservation | Significant concern — stack with peptides | Significant concern — stack with peptides |
| Available to Track | Protocol app compound library | Protocol app compound library |
Can You Get Retatrutide in 2026?
Retatrutide (LY3437943, developed by Eli Lilly) is not FDA approved as of mid-2026 and cannot be obtained through compounding pharmacies. Unlike Tirzepatide, which has an approved reference product (Mounjaro/Zepbound) and was available through compounders during shortage periods, Retatrutide has no approved version and therefore no compounding pathway under current FDA rules.
It is available as a research chemical from peptide suppliers -- legal for laboratory research use only, not for human injection. Quality, purity, and dosing accuracy vary significantly between suppliers. Anyone using research-grade Retatrutide should verify third-party testing. See our guide to evaluating peptide quality and reading a Certificate of Analysis.
Phase 3 data is expected to complete in late 2026 to early 2027, with FDA approval possible by late 2027 at the earliest. When approved, it will likely be available only by prescription -- similar to Tirzepatide's current path.
Retatrutide or Tirzepatide: Which Makes More Sense?
Tirzepatide may be the better choice if:
- •You want an FDA-approved treatment with extensive safety data
- •You have any history of cardiovascular issues or elevated resting heart rate
- •You want compounding pharmacy access for cost savings
- •You prefer a well-established titration protocol with predictable dosing
- •Long-term durability data matters to your decision
Retatrutide may be worth monitoring closely if:
- •You have previously plateaued on Tirzepatide or Semaglutide
- •Maximum fat loss is the primary goal and cardiac risk is low
- •You are willing to use research-grade compound with quality verification
- •You are tracking all vitals closely, including resting heart rate
- •You want to be positioned for early access when FDA approval arrives
Why Precision Tracking Matters More With Both Drugs
GLP-1 drugs at therapeutic doses require careful tracking for a straightforward reason: they work so well at suppressing appetite that users routinely undereat protein, lose lean mass, and experience side effects that dose-logging would catch early.
For Retatrutide specifically, tracking resting heart rate alongside dose timing helps identify whether the glucagon-driven cardiovascular effect is dose-dependent or constant -- information that matters when deciding whether to titrate up or hold.
Frequently Asked Questions
Is Retatrutide better than Tirzepatide for weight loss?
Phase 2 data suggests Retatrutide produces slightly greater weight loss (approximately 24.2% vs 20.9% for Tirzepatide), but these numbers come from different trial designs and timeframes. No head-to-head trial exists yet. Retatrutide is not FDA approved, and its additional side effects -- particularly elevated resting heart rate -- need to be weighed against the marginal weight loss advantage.
What makes Retatrutide a triple agonist?
Retatrutide activates three hormone receptors: GLP-1 (appetite suppression, blood sugar), GIP (insulin sensitivity, GI tolerability), and glucagon (energy expenditure, fat oxidation). Tirzepatide activates only the first two. The glucagon component is what drives Retatrutide's additional fat loss and its elevated heart rate side effect.
Does Retatrutide cause heart rate increase?
Yes. Phase 2 trials showed an average resting heart rate increase of 4-5 bpm in Retatrutide recipients. This is attributed to glucagon receptor activity and its cardiovascular effects. Patients with existing cardiac conditions, arrhythmias, or elevated baseline heart rate should discuss this with a physician before considering Retatrutide.
Can I stack peptides with Tirzepatide or Retatrutide?
Many clinicians and self-experimenters do. The GLP-1 Defense Stack -- combining the GLP-1 drug with Ipamorelin to support the GH/IGF-1 axis and preserve lean mass -- has become one of the most searched protocols in the peptide community. See our Stack Planner for the full evidence-graded protocol and dosing guidance.
Track Your GLP-1 Protocol
Protocol for iOS lets you log doses, visualize your PK curve, and track resting heart rate and weight alongside your compound schedule -- all on-device, no cloud sync required.
References
- [1]Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- [2]Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- [3]Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514-526.
- [4]Frías JP, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.
Citations are provided for informational context. This article does not reproduce copyrighted content from these sources.
Share this article